IRPPS-Institute for Research on Population and Social Policies of the Italian National Research Council, Fisciano, Salerno, Italy.
Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Diabetes Res Clin Pract. 2018 Sep;143:420-427. doi: 10.1016/j.diabres.2018.02.044. Epub 2018 Mar 26.
Diabetes and cancer frequently coexist in the same subject, often having relevant effects on the management and prognosis of the oncologic patient. However, existing guidelines do not deal with many clinical issues in this setting appropriately. In evaluating the opinions of Diabetologists and Oncologists dealing with diabetes care in people with cancer, the Italian Association of Diabetologists (AMD) promoted a dedicated exploratory survey.
The survey was carried out through the web or handily delivered printed copies between October 2014 and April 2015, in Italy. It was composed of 27 questions intended to gather information on the characteristics of participants and to examine their clinical habits in this context, and participation was totally free and anonymous.
A total of 252 physicians participated in the survey. Diabetologists accounted for 51.1% of respondents. According to survey results, in spite of the presence of diabetes (or diabetic complications) worsening the outcome of cancer treatments, the counseling or intervention of a Diabetologist was only required for less than two-thirds of hospitalized patients. For subjects with a life expectancy of months, 80% of specialists considered a glycemic target of 120-250 mg/dL optimal whereas Oncologists were more likely to consider a range of 180-360 mg/dL for patients with a shorter life expectancy. Furthermore, 1 participant out of 3 indicated 1-4 measurements/day as the most appropriate frequency for blood glucose monitoring including in the palliative setting. Insulin was the therapy of choice for the majority of respondents albeit with different routes of administration.
This survey provides interesting preliminary data that could help facilitate and optimize the management of patients with cancer and diabetes, promoting the delivery of an organic answer to fragmented assistance, to potentially inappropriate behaviors, and to a tailored therapy in a context of particular clinical fragility.
糖尿病和癌症经常同时存在于同一患者身上,这常常对肿瘤患者的管理和预后产生相关影响。然而,现有的指南并没有恰当地处理这一背景下的许多临床问题。在评估处理癌症患者糖尿病护理的糖尿病专家和肿瘤学家的意见时,意大利糖尿病学会(AMD)推动了一项专门的探索性调查。
该调查于 2014 年 10 月至 2015 年 4 月在意大利通过网络或便捷的纸质副本进行。它由 27 个问题组成,旨在收集参与者的特征信息,并检查他们在这种情况下的临床习惯,参与完全是免费和匿名的。
共有 252 名医生参与了这项调查。糖尿病专家占受访者的 51.1%。根据调查结果,尽管糖尿病(或糖尿病并发症)会使癌症治疗的结果恶化,但不到三分之二的住院患者需要咨询或干预糖尿病专家。对于预期寿命为几个月的患者,80%的专家认为血糖目标为 120-250mg/dL 是最佳的,而对于预期寿命较短的患者,肿瘤学家更倾向于认为血糖目标为 180-360mg/dL。此外,三分之一的参与者表示,在姑息治疗中,每天 1-4 次的血糖监测是最适当的频率。胰岛素是大多数受访者的首选治疗方法,但给药途径不同。
这项调查提供了有趣的初步数据,有助于促进和优化癌症和糖尿病患者的管理,为提供有机的综合医疗服务、潜在的不适当行为以及在特殊临床脆弱性背景下的个体化治疗提供帮助。